Home / Health / Here is what you should know about Moderna’s COVID-19 vaccine candidate

Here is what you should know about Moderna’s COVID-19 vaccine candidate

The World Health Organization (WHO) recently named AstraZeneca’s AZD1222 and Moderna’s mRNA-1273 as two of the leading candidates in the COVID-19 vaccine race.

Here we look at what Moderna’s mRNA-1273 has to offer.

About mRNA-1273, Moderna’s Vaccine Candidate Against COVID-19

mRNA-1273 is an mRNA vaccine candidate against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the US National Institutes of Health (NIH).

On June 11, 2020, Moderna announced that enrollment of younger adults (n=300) and the sentinel group of older adults (n=50) in its Phase 2 study of mRNA-1273 was complete, and that its Phase 3 study of approximately 30,000 participants, is expected to begin in July 2020.

mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases.

The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates.

Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Check Also

PTI’s social media guru to head govt digital wing

KARACHI: After assessing 500 applications received for the digital media wing, the government has appointed …